新型抗精神病药物与儿童及青少年肥胖。我们应如何评估药物相关的体重增加？
Newer antipsychotic drugs and obesity in children and adolescents. How should we assess drug-associated weight gain?
作者信息
Vieweg W V R, Sood A B, Pandurangi A, Silverman J J
机构信息
Department of Psychiatry, Medical College of Virginia, Virginia Commonwealth University, Richmond, VA 23238-5414, USA.
出版信息
Acta Psychiatr Scand. 2005 Mar;111(3):177-84. doi: 10.1111/j.1600-0447.2004.00444.x.
OBJECTIVE
Antipsychotic drugs may contribute to weight gain in children and adolescents.
METHOD
We used Medline's PubMed in the pediatric age using key words 'weight gain' and 'obesity', for each newer antipsychotic drug.
RESULTS
We found 21 articles linking weight gain and obesity with newer antipsychotic drugs among youths. Risperidone was the most commonly cited agent. Weight gain from olanzapine was the largest among the more commonly prescribed newer agents. All studies reported absolute weight gain. Only a few studies used the better measure of body mass index (BMI). None incorporated growth charts to allow for changes in weight and height over time because of growth.
CONCLUSION
Weight gain may be a major problem when prescribing newer antipsychotic drugs in the pediatric population. Risperidone is associated with less weight gain than olanzapine. Published reports and studies have not utilized state-of-the-art techniques using BMI with readily available growth charts.
目的
抗精神病药物可能会导致儿童和青少年体重增加。
方法
我们在儿科年龄段使用Medline的PubMed，针对每种新型抗精神病药物使用关键词“体重增加”“肥胖”进行查找。
结果
我们发现21篇文章将青少年体重增加和肥胖与新型抗精神病药物联系起来。利培酮是被引用最多的药物。在更常用的新型药物中，奥氮平导致的体重增加最多。所有研究均报告了绝对体重增加情况。只有少数研究使用了更好的体重指数（BMI）测量方法。没有一项研究纳入生长图表以考虑因生长导致的体重和身高随时间的变化。
结论
在儿科人群中开具新型抗精神病药物时，体重增加可能是一个主要问题。与奥氮平相比，利培酮导致的体重增加较少。已发表的报告和研究未使用结合BMI和现成生长图表的先进技术。
Zotero 插件